When Calibrators Require Carrier-Free Antigen
Updated 2026-09-28
Carrier proteins and excipients can shift a calibration curve. Here is when a carrier-free antigen is the correct choice for assay calibrators.
What Carrier-Free Actually Means
Carrier-free describes an antigen preparation supplied without added protein stabilisers such as bovine serum albumin, gelatin or casein. The purified protein may still contain trace process-related material, but no protein is deliberately added as a carrier. The term does not imply the absence of every contaminant, only the absence of an intentionally added carrier. This matters because calibrators define the response of an assay, and anything added to the calibrator matrix becomes part of that definition. When a calibrator is prepared from carrier-containing stock, the added protein is present at every point of the curve.
How Carrier Protein Disturbs a Curve
Carrier proteins can take part in the assay itself. BSA and gelatin are common blocking agents; they can adsorb to the solid phase, alter non-specific binding, or compete with the analyte for antibody sites. Their effect may be small at one concentration and larger when the calibrator is diluted across a wide range, which can bend the curve and misstate the upper or lower region. A carrier-free antigen lets the developer control the matrix deliberately, adding only the stabilisers that have been tested in that specific immunoassay.
Deciding for Your Assay
Choose a carrier-free antigen when the calibrator matrix must be fully defined, when the assay is sensitive to non-specific binding, or when the curve must transfer between platforms. A carrier-containing preparation can still be appropriate for immunization, general biochemical work or applications where the added protein is irrelevant. The practical question is whether the added protein will be present at a concentration that influences the measured signal. If it will be, control it. If it will not, the choice is yours.
How to test whether carrier is the problem
The question is not whether the carrier is present but whether it changes your measurement, and that is answerable with a comparison rather than an argument. Prepare two calibrator series from the same antigen stock, one spiked with a defined amount of the carrier protein you suspect and one without, and run both across the full working range. If the curves are superimposable the carrier is not your problem. If they diverge at the ends but agree at mid-range, the carrier is affecting non-specific binding in exactly the region where clinical decisions are made. Also worth testing is whether the effect scales with the carrier concentration rather than with the antigen, which is the signature of a matrix artefact rather than a genuine calibration difference. A short experiment of this kind settles a question that otherwise tends to be decided by supplier marketing.
Carrier-free is not automatically better
Carrier-free is a specification, not a quality judgement, and in some applications the carrier is doing useful work. Proteins at low concentration adsorb to plastic and to the walls of tubes, and a carrier protein competes for those surfaces so that your analyte stays in solution; a carrier-free preparation at very low concentration can therefore lose material to the container, which is a worse failure than a slightly raised background. Carriers are also legitimate in immunisation protocols, where the added protein is irrelevant to the outcome, and in general biochemical work where the measurement is not a binding assay. Choose carrier-free when the calibrator matrix has to be fully defined, when the assay is sensitive to non-specific binding, or when a curve must transfer between platforms — and choose otherwise when the material is dilute or the application is not analytical.
References
These references concern the analytes and the analytical literature — not our materials. Each entry was checked against its PubMed record, and the PMID links to that record so you can verify the details yourself rather than taking our word for it.
- Findlay JW, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21:1249-73. PMID 10708409
Related materials
Human Recombinant Soluble ST2 (sST2 / IL1RL1) →Recombinant Cardiac Troponin I (cTnI) →Request a Quote or Sample
Tell us your application, target purity and quantity — we reply within one business day.